24430-26-0

Basic information

• Product Name: 3-nitro-4-ethoxyacetophenone
• Synonyms: 3-nitro-4-ethoxyacetophenone;1-(4-ethoxy-3-nitrophenyl)ethanone
• CAS NO: 24430-26-0
• Molecular Formula: C₁₀H₁₁NO₄
• Molecular Weight: 209.2
• Mol File: 24430-26-0.mol

Chemical Properties

• Melting Point: 67-68 °C
• Boiling Point: 328.2±22.0 °C(Predicted)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• CAS DataBase Reference: 3-nitro-4-ethoxyacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 3-nitro-4-ethoxyacetophenone(24430-26-0)
• EPA Substance Registry System: 3-nitro-4-ethoxyacetophenone(24430-26-0)

Safety Data

• Hazardous Substances Data: 24430-26-0(Hazardous Substances Data)

Upstream product

• 1676-63-7 4'-ethoxyacetophenone 
• 99-93-4 4-Hydroxyacetophenone 
• 74-96-4 ethyl bromide 
• 6322-56-1 4'-hydroxy-3'-nitroacetophenone 
• 64-17-5 ethanol 
• 400-93-1 3-nitro-4-fluoroacetophenone 

Relevant articles and documents

NEW TARGETED CYTOTOXIC ISOCOMBRETAQUINOLINE DERIVATIVES AND CONJUGATES THEREOF

The present invention is directed to novel natural product-derived combretastatin- based compounds useful as payloads in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new isoNH2CombretaQuinoline compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer.

Dichloroacetophenones targeting at pyruvate dehydrogenase kinase 1 with improved selectivity and antiproliferative activity: Synthesis and structure-activity relationships

Dichloroacetophenone is a pyruvate dehydrogenase kinase 1 (PDK1) inhibitor with suboptimal kinase selectivity. Herein, we report the synthesis and biological evaluation of a series of novel dichloroacetophenones. Structure-activity relationship analyses (SARs) enabled us to identify three potent compounds, namely 54, 55, and 64, which inhibited PDK1 function, activated pyruvate dehydrogenase complex, and reduced the proliferation of NCI-H1975 cells. Mitochondrial bioenergetics assay suggested that 54, 55, and 64 enhanced the oxidative phosphorylation in cancer cells, which might contribute to the observed anti-proliferation effects. Collectively, these results suggested that 54, 55, and 64 could be promising compounds for the development of potent PDK1 inhibitors.

COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED

The invention relates to a compound for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated characterized by a general formula (1) and a compound according to formula (3).

HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS

Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.